Magstim Passes Compliance with Strict European Union Medical Device Regulations Expanding Magstim Access to Entire EU Marketplace WHITLAND, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Magstim has ...
The FDA clearance now allows physicians and nurse practitioners to gain authorization from insurance providers to treat adolescent patients. The Food and Drug Administration (FDA) has cleared ...
The Horizon® 3.0 Inspire has a compact design allowing for easier portability. The Food and Drug Administration (FDA) has cleared Magstim’s Horizon ® 3.0 Inspire for the treatment of major depressive ...
Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment for depression when medications aren't working.
Transcranial magnetic stimulation sounds like — and looks like — something you'd find in a science fiction movie, but it's a real treatment option. This noninvasive therapy uses strong magnets to ...
An electromagnetic therapy for depression shouldn't damage a person's pre-existing implantable cardioverter-defibrillator (ICD), multiple experiments indicated. There was a low risk of ICD damage or ...
Medicare covers transcranial magnetic stimulation (TMS) as a treatment for severe major depressive disorder (MDD) if it is deemed medically necessary, but coverage is limited to a maximum of 6 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results